Our findings offer insights into aberrant TAZ overexpression underlying tumorigenesis and may advance the development of therapeutic approaches to disrupt the USP7-TAZ axis in HNSCC. This evidence concerns the gene USP7 and head and neck squamous cell carcinoma.